Australian biotech market watch 22/01/10
Friday, 22 January, 2010
Health and biotech stocks have followed the All Ordinaries on a slide in morning trading on the back of a weak week in Wall St and concerns over the global economy. The All Ords are down 1.8% in early afternoon trading, with the S&P Health Care index experiencing a slight recovery from this morning, down only 0.25% as of 1pm.
One of the biggest drops was had by Mesoblast (ASX:MSB), which shed 18c to $1.95, although it's still up 44% over the past month.
Sirtex Medical (ASX:SRX) has also dropped 6%, down to $7.07, and Prima BioMed is back to 17c after bumping to 18c at yesterday's close.
pSivida (ASX:PVA) shed 23c, down to $4.05, and Patrys (ASX:PAB) has continued its decline of the past week, down 3.9% to 12.5c.
It wasn't all bad news, though. Cochlear (ASX:COH) managed to put on $1.69, to $66.12, in a strong morning's trading.
Xenotransplantation specialists, Living Cell Technology, has had some ups and downs over the past week, but recovered today to the tune of 2.4%, up to 21c.
CSL (ASX:CSL) was up slightly, adding 8c to $31.15, and ResMed (ASX:RMD) was steady.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
